• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Latest News

Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS
Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS

July 24th 2024

Researchers behind the phase 3 studies gave pearls into the study methods, results, and what is up next.

Physicians Should Prepare for Potential Acne Vulgaris Misinformation Correction, Report Says
Physicians Should Prepare for Potential Acne Vulgaris Misinformation Correction, Report Says

July 24th 2024

Deep Histological Margins Do Not Increase cSCC Recurrence Risk if Tumor is Fully Excised
Deep Histological Margins Do Not Increase cSCC Recurrence Risk if Tumor is Fully Excised

July 24th 2024

Managing Food Allergies with Dupilumab in Pediatric Dermatology
Managing Food Allergies with Dupilumab in Pediatric Dermatology

July 24th 2024

Latex Gloves and the Americans With Disabilities Act
Latex Gloves and the Americans With Disabilities Act

July 24th 2024

Meet the 2024 Quarterly Editor in Chiefs
Reimbursement Success for Laser Treatments
Breakthroughs in Pediatric Atopic Dermatitis
Subscribe Now for Free - eNL
Explore Our Conference Coverage
3
Subscribe for Free - Print
Stay Informed!
Don't miss the latest in dermatology news

Conference Coverage

View All
Hematologic Safety of Ruxolitinib Cream in Children with Atopic Dermatitis
Hematologic Safety of Ruxolitinib Cream in Children with Atopic Dermatitis

July 19th 2024

Advanced Practice Providers Share Insights at the 2024 Society for Pediatric Dermatology Annual Meeting
Advanced Practice Providers Share Insights at the 2024 Society for Pediatric Dermatology Annual Meeting

July 19th 2024

Phase 3 Ruxolitinib Study Shows Higher Rates of Adolescent Repigmentation
Phase 3 Ruxolitinib Study Shows Higher Rates of Adolescent Repigmentation

July 16th 2024

Recap: 2024 Society for Pediatric Dermatology Annual Meeting
Recap: 2024 Society for Pediatric Dermatology Annual Meeting

July 15th 2024

Latest Videos

All News

© 2024 MJH Life Sciences

All rights reserved.